吡马范色林与非典型抗精神病药治疗帕金森病精神病的死亡率比较
这项回顾性新用药者队列研究基于Medicare受益人数据,比较吡马范色林(N=3,227)与非典型抗精神病药(N=18,442)在帕金森病患者中的死亡率。治疗前180天内,吡马范色林组死亡率约低35%(HR=0.65,95%CI=0.53-0.79),但180天后无额外生存优势(HR=1.05,95%CI=0.82-1.33)。吡马范色林在养老院患者中未显示死亡率优势。
要点
- 治疗前180天,吡马范色林组死亡率较非典型抗精神病药组低约35%(HR=0.65,95%CI=0.53-0.79)。
- 治疗超过180天后,两组死亡率无显著差异(HR=1.05,95%CI=0.82-1.33)。
- 吡马范色林在养老院患者中未显示死亡率优势,优势仅见于社区居住患者。
核心结论
- 吡马范色林治疗前180天死亡率低于非典型抗精神病药,但该优势仅见于社区居住患者,不见于养老院患者。
- 治疗超过180天后,吡马范色林无额外死亡率优势。
研究设计与样本
- 回顾性新用药者队列研究,使用Medicare受益人数据,纳入2016年4月至2019年3月启动吡马范色林(N=3,227)或非典型抗精神病药(N=18,442)的帕金森病患者。
- 采用分段比例风险回归分析1-180天和181天以上的治疗期,并通过逆概率治疗加权(IPTW)控制混杂。
主要发现
- 吡马范色林使用者平均年龄约78岁,45%为女性。
- IPTW前,非典型抗精神病药组部分合并症更常见;IPTW后两组合并症均衡。
- 治疗前180天,吡马范色林组死亡率约低35%(HR=0.65,95%CI=0.53-0.79),约每30例非典型抗精神病药治疗患者多1例死亡。
- 治疗超过180天,吡马范色林无额外死亡率优势(HR=1.05,95%CI=0.82-1.33)。
- 吡马范色林在养老院患者中未显示死亡率优势。
关键数值与推荐
- 前180天全因死亡HR=0.65(95%CI=0.53-0.79),吡马范色林组较非典型抗精神病药组死亡率低约35%。
- 181天及以上全因死亡HR=1.05(95%CI=0.82-1.33),两组无显著差异。
- 约每30例非典型抗精神病药治疗患者多1例死亡(前180天)。
临床怎么用
- 对于社区居住的帕金森病精神病患者,前180天治疗中吡马范色林相比非典型抗精神病药与更低死亡率相关。
- 吡马范色林在养老院患者中未显示死亡率优势。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pimavanserin, a serotonin 5-HT2 antagonist, is indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. In premarketing trials in patients with Parkinson's disease psychosis, 11% of patients died during open-label pimavanserin treatment. Antipsychotics, which are used off-label in Parkinson's disease psychosis, increase mortality in dementia patients. The authors compared mortality with pimavanserin and atypical antipsychotics in a large database. METHODS: This was a retrospective new-user cohort study of Medicare beneficiaries with Parkinson's disease initiating pimavanserin (N=3,227) or atypical antipsychotics (N=18,442) from April 2016 to March 2019. All-cause mortality hazard ratios and 95% confidence intervals were estimated for pimavanserin compared with atypical antipsychotics, using segmented proportional hazards regression over 1-180 and 181+ days of treatment. Potential confounding was addressed through inverse probability of treatment weighting (IPTW). RESULTS: Pimavanserin users had a mean age of approximately 78 years, and 45% were female. Before IPTW, some comorbidities were more prevalent in atypical antipsychotic users; after IPTW, comorbidities were well balanced between groups. In the first 180 days of treatment, mortality was approximately 35% lower with pimavanserin than with atypical antipsychotics (hazard ratio=0.65, 95% CI=0.53, 0.79), with approximately one excess death per 30 atypical antipsychotic-treated patients; however, during treatment beyond 180 days, there was no additional mortality advantage with pimavanserin (hazard ratio=1.05, 95% CI=0.82, 1.33). Pimavanserin showed no mortality advantage in nursing home patients. CONCLUSIONS: Pimavanserin use was associated with lower mortality than atypical antipsychotic use during the first 180 days of treatment, but only in community-dwelling patients, not nursing home residents.
引用
- Mosholder AD, Ma Y, Akhtar S, et al. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries. Am J Psychiatry. 2022. PMID: 35702829. doi:10.1176/appi.ajp.21090876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。